ArticleFrontiers in immunology2025
Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells.
Xinlin Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
ArticleFrontiers in immunology2025
Xinlin Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.